Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Summary

Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial.

Timeline

Start

2022-01-01

Primary completion

2023-03-31

Completion

2025-03-31

Drugs

Indications